Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment

F Piñero, M Dirchwolf, MG Pessôa - Cells, 2020 - mdpi.com
Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death
worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and …

[HTML][HTML] Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma

H Hanif, MJ Ali, AT Susheela, IW Khan… - World Journal of …, 2022 - ncbi.nlm.nih.gov
Alpha-fetoprotein (AFP) is an oncofetal glycoprotein that has been used as a tumor marker
for hepatocellular carcinoma (HCC) in combination with ultrasound and other imaging …

AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

AG Singal, JM Llovet, M Yarchoan, N Mehta… - Hepatology, 2023 - journals.lww.com
This guidance document provides an updated approach to the prevention, diagnosis, and
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …

Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases

JA Marrero, LM Kulik, CB Sirlin, AX Zhu, RS Finn… - Hepatology, 2018 - journals.lww.com
This guidance provides a data-supported approach to the diagnosis, staging, and treatment
of patients diagnosed with hepatocellular carcinoma (HCC). A guidance document is …

[HTML][HTML] Biomarkers for the early diagnosis of hepatocellular carcinoma

N Tsuchiya, Y Sawada, I Endo, K Saito… - World journal of …, 2015 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading
cause of cancer-related deaths worldwide. Although the prognosis of patients with HCC is …

The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers

PJ Johnson, SJ Pirrie, TF Cox, S Berhane… - … Biomarkers & Prevention, 2014 - AACR
Background: Hepatocellular carcinoma is a common complication of chronic liver disease
(CLD), and is conventionally diagnosed by radiological means. We aimed to build a …

Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis

M Sherman - Seminars in liver disease, 2010 - thieme-connect.com
Hepatocellular carcinoma (HCC) is increasing in incidence in many countries, and is the
most common cause of death in patients with cirrhosis. With regular surveillance, small early …

Tumor markers for hepatocellular carcinoma

YJ Zhao, Q Ju, GC Li - Molecular and clinical oncology, 2013 - spandidos-publications.com
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with a high
rate of morbidity and mortality. HCC affects approximately one million individuals annually …

Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey

M Wang, J Zhu, DM Lubman, C Gao - Clinical Chemistry and …, 2019 - degruyter.com
Glycosylation is among the most important post-translational modifications for proteins and
is of intrinsic complex character compared with DNAs and naked proteins. Indeed, over 50 …

AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC

K Yamamoto, H Imamura, Y Matsuyama… - Journal of …, 2010 - Springer
Abstract Background Alpha-fetoprotein (AFP), lens culinaris agglutinin-reactive fraction of
AFP (AFP-L3), des-γ-carboxy prothrombin (DCP), and Golgi protein-73 (GP73) have been …